- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01702363
Long-term Safety Study for GSK573719 in Japanese (AC4115361)
A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.
연구 개요
상세 설명
Chronic Obstructive Pulmonary Disease (COPD) treatment guidelines recommend an incremental approach to pharmacological treatment as the disease state worsens, involving the use of combinations of drug classes with different or complementary mechanisms of action [Celli, 2004, GOLD 2009]. As disease progresses from mild to moderate, regular treatment with one or more long-acting bronchodilators is recommended. Inhaled bronchodilators, including beta2 agonists and anticholinergics are included with inhaled corticosteroids (ICS) therapy and are mainstays of therapy in patients diagnosed with COPD. Since GSK573719 Inhalation Powder is expected to be used for chronic management of COPD as long-acting muscarinic antagonist (LAMA), this study is intended to evaluate the safety and tolerability of long-term administration of GSK573719 Inhalation Powder 125 mcg in Japanese patients with COPD at doses possibly used to be in Japan.
In this study, patient safety will also be monitored by evaluating pulmonary function and clinical symptoms.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Fukuoka, 일본, 811-1347
- GSK Investigational Site
-
Gunma, 일본, 371-0048
- GSK Investigational Site
-
Hokkaido, 일본, 080-0805
- GSK Investigational Site
-
Hyogo, 일본, 670-0849
- GSK Investigational Site
-
Ibaraki, 일본, 300-0053
- GSK Investigational Site
-
Ibaraki, 일본, 302-0022
- GSK Investigational Site
-
Ishikawa, 일본, 920-8610
- GSK Investigational Site
-
Kanagawa, 일본, 239-0821
- GSK Investigational Site
-
Kyoto, 일본, 601-1495
- GSK Investigational Site
-
Miyagi, 일본, 983-0824
- GSK Investigational Site
-
Nagano, 일본, 391-0011
- GSK Investigational Site
-
Oita, 일본, 870-0921
- GSK Investigational Site
-
Oita, 일본, 876-0047
- GSK Investigational Site
-
Osaka, 일본, 589-0022
- GSK Investigational Site
-
Osaka, 일본, 530-0001
- GSK Investigational Site
-
Shizuoka, 일본, 436-0022
- GSK Investigational Site
-
Tokyo, 일본, 103-0027
- GSK Investigational Site
-
Tokyo, 일본, 153-8934
- GSK Investigational Site
-
Tokyo, 일본, 192-0903
- GSK Investigational Site
-
Yamanashi, 일본, 400-0031
- GSK Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Outpatient.
- A signed and dated written informed consent prior to study participation.
- Japanese subjects 40 years of age or older at Visit 1.
- Male or female subjects. A female is eligible if she is of: Non-child bearing potential or Child bearing potential agrees to one of the contraceptive methods.
- Subjects with a clinical history of COPD in accordance with the definition by COPD domestic guideline.
- Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at Visit 1.
- Subject with a measured post-salbutamol forced expiratory volume/forced vital capacity (FEV1/FVC) ratio of <70% and Subjects with a measured post-salbutamol FEV1 <80% of predicted normal values.
Exclusion Criteria (Visit 1):
- Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- A current diagnosis of asthma.
- Known respiratory disorders other than COPD.
- Subjects with historical or current evidence of clinically significant abnormalities that are uncontrolled.
- A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD.
- Allergy or hypersensitivity to muscarinic, beta2-agonist, lactose/milk protein or magnesium stearate or a condition that contraindicates participation.
- Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
- Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
- An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1.
- Significantly abnormal finding from clinical chemistry or hematology, tests at Visit 1.
- Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day.
- Regular use (prescribed every day, not for as-needed use) of short-acting bronchodilators (e.g., salbutamol) via nebulized therapy.
- Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1.
- A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
- Affiliation with Investigator Site.
- Previous use of GSK573719, the GSK573719/GW642444 combination.
- Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer).
Exclusion Criteria (Visit 2):
- COPD Exacerbation during run-in period: Subject must not have experienced a COPD exacerbation or a lower respiratory tract infection during run-in or at Visit 2.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: GSK573719
125mcg
|
GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) Throughout the Treatment Period
기간: From the first dose of study medication up to 52 weeks
|
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of the study medication, whether or not considered related to the study medication.
An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the study medication.
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect, or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury.
Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations.
|
From the first dose of study medication up to 52 weeks
|
Number of Participants With AEs Classified by the Indicated Maximum Grade Severity Throughout the Treatment Period
기간: From the first dose of study medication up to 52 weeks
|
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of the study medication, whether or not considered related to the study medication.
An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the study medication.
AEs were classified according to intensity based upon the investigators' clinical judgment.
The intensity was categorized as: mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities); moderate (an event that is sufficiently discomforting to interfere with normal everyday activities); or severe (an event that prevents normal everyday activities).
|
From the first dose of study medication up to 52 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Basophil, Eosinophil, Lymphocyte, Monocyte, and Total Neutrophil Values at Baseline (BL) (Week -2), Week 12, Week 24, Week 36, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
기간: BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD Visit, and Week 52/WD Visit
|
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD Visit (conducted for participants who completed the Week 24 Visit or withdrew before Week 24), and Week 52/WD Visit (conducted for participants who completed the Week 52 Visit or withdrew before Week 52).
The BL value for clinical laboratory tests was the value recorded on Week -2 (Screening Visit).
|
BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD Visit, and Week 52/WD Visit
|
Eosinophil Values, Total Neutrophil Values, Platelet Count, and White Blood Cell (WBC) Count at BL (Week -2), Week 12, Week 24, Week 36, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
기간: BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 Visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 Visit or withdrew before Week 52).
The BL value for clinical laboratory tests was the value recorded on Week -2 (Screening Visit).
|
BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Hemoglobin, Albumin, and Total Protein Values at BL (Week -2), Week 12, Week 24, Week 36, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
기간: BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 Visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 Visit or withdrew before Week 52).
The BL value for clinical laboratory tests was the value recorded on Week -2 (Screening Visit).
|
BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Hematocrit Values at BL (Week -2), Week 12, Week 24, Week 36, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
기간: BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Blood samples were collected for the measurement of hematocrit at the following time points: BL (Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 Visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 Visit or withdrew before Week 52).
The BL value for clinical laboratory tests was the value recorded on Week -2 (Screening Visit).
|
BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, and Gamma Glutamyl Transferase (GGT) Values at BL (Week -2), Week 12, Week 24, Week 36, Week 52, the WD Visit, Week 24/WD, and Week 52/WD
기간: BL (Screening Visit: Week -2), Week 12, Week 24, Week36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 Visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 Visit or withdrew before Week 52).
The BL value for clinical laboratory tests was the value recorded on Week -2 (Screening Visit).
|
BL (Screening Visit: Week -2), Week 12, Week 24, Week36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid Values at BL (Week -2), Week 12, Week 24, Week 36, Week 52, the WD Visit, Week 24/WD, and Week 52/WD
기간: BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 Visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 Visit or withdrew before Week 52).
The BL value for clinical laboratory tests was the value recorded on Week -2 (Screening Visit).
|
BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Calcium, Chloride, Glucose, Carbon Dioxide/Bicarbonate (CO2/HCO3), Potassium, Sodium, Inorganic Phosphorus, and Urea/Blood Urea Nitrogen (Urea/BUN) Values at BL (Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
기간: BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 Visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 Visit or withdrew before Week 52).
The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening Visit).
|
BL (Screening Visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
|
Change From BL in Blood Pressure Throughout the Treatment Period
기간: BL(Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD Visit, and Week 52/WD Visit
|
Blood pressure measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP).
Blood pressure was measured in a sitting position after the participant was kept at rest for at least 5 minutes.
Change from BL was calculated as the assessment value at the time of interest minus the BL value.
The BL value was recorded at Week 0. The WD Visit was conducted for participants who withdrew at any point during the study.
The Week 24/WD Visit was conducted for participants who completed the Week 24 Visit or withdrew before Week 24.
The Week 52/WD Visit was conducted for participants who completed the Week 52 Visit or withdrew before Week 52.
|
BL(Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD Visit, and Week 52/WD Visit
|
Change From BL in Heart Rate Throughout the Treatment Period
기간: BL (Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD Visit, and Week 52/WD Visit
|
Heart rate was measured in a sitting position after the participant was kept at rest for at least 5 minutes.
Change from BL was calculated as the assessment value at the time of interest minus the BL value.
The BL value was recorded at Week 0. The WD Visit was conducted for participants who withdrew at any point during the study.
The Week 24/WD Visit was conducted for participants who completed the Week 24 Visit or withdrew before Week 24.
The Week 52/WD Visit was conducted for participants who completed the Week 52 Visit or withdrew before Week 52.
|
BL (Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD Visit, and Week 52/WD Visit
|
Number of Participants With Abnormal Findings in 12-lead Electrocardiograms (ECG) at the Indicated Time Points
기간: BL (Screening Visit: Week -2), Week 12, Week 24,Week 36, Week 52, WD Visit, Week 24/WD Visit, and Week 52/WD Visit
|
A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes.
Data are presented as clinically significant (CS) or not clinically significant (NCS) abnormal findings.
An abnormal and significant ECG finding includes the presence of a QT interval corrected for heart rate (QTc interval) >500 milliseconds (msec) or an uncorrected QT interval >600 msec, for participants with Bundle Branch Block QTc >530 msec based on an average QTc value of triplicate ECGs.
The study investigator determined if the abnormal ECG finding was CS or NCS.
The WD Visit was conducted for participants who withdrew at any point during the study.
The Week 24/WD and Week 52/WD Visits were conducted for participants who completed the Week 24 Visit or withdrew before Week 24 and completed the Week 52 Visit or withdrew before Week 52, respectively.
The BL value for clinical laboratory tests was the value recorded on Week -2 (Screening Visit).
|
BL (Screening Visit: Week -2), Week 12, Week 24,Week 36, Week 52, WD Visit, Week 24/WD Visit, and Week 52/WD Visit
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 115361
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
연구 데이터/문서
-
주석이 달린 사례 보고서 양식
정보 식별자: 115361정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
정보에 입각한 동의서
정보 식별자: 115361정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
통계 분석 계획
정보 식별자: 115361정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
개별 참가자 데이터 세트
정보 식별자: 115361정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
임상 연구 보고서
정보 식별자: 115361정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
데이터 세트 사양
정보 식별자: 115361정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
연구 프로토콜
정보 식별자: 115361정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
GSK573719에 대한 임상 시험
-
GlaxoSmithKline완전한
-
GlaxoSmithKline완전한폐질환, 만성 폐쇄성헝가리, 슬로바키아
-
GlaxoSmithKline완전한폐질환, 만성 폐쇄성대만, 태국, 중국, 필리핀 제도, 대한민국
-
GlaxoSmithKline완전한폐질환, 만성 폐쇄성남아프리카, 미국, 캐나다, 우크라이나, 영국, 덴마크, 체코
-
GlaxoSmithKline완전한